Boston Scientific Sticks to Solo Strategy as Peers Consolidate

  • CEO Mahoney says research is more cost-effective than M&A
  • Company seeks ‘opportunistic’ deals such as Cosman purchase

Boston Scientific Corp. Chief Executive Officer Mike Mahoney says he’s happy resisting the consolidation craze sweeping the medical device industry, and will stay focused on internal research and development to maintain the company’s leadership position.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.